ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysisA. Clamp, Jonathan A. Ledermann, J. Weon-Kim et al.|Annals of Oncology|2017Cited by 51
1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysisA. Clamp, JA Ledermann, Iain A. McNeish et al.|Annals of Oncology|2025Cited by 3